Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Gamida Cell Ltd (GMDA)

Gamida Cell Ltd (GMDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 139,712
  • Shares Outstanding, K 59,200
  • Annual Sales, $ 0 K
  • Annual Income, $ -89,790 K
  • 60-Month Beta 1.82
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.54
Trade GMDA with:

Options Overview Details

View History
  • Implied Volatility 136.97% ( +15.61%)
  • Historical Volatility 68.20%
  • IV Percentile 84%
  • IV Rank 53.65%
  • IV High 211.20% on 01/31/22
  • IV Low 51.07% on 09/10/21
  • Put/Call Vol Ratio 0.10
  • Today's Volume 57
  • Volume Avg (30-Day) 64
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 8,485
  • Open Int (30-Day) 8,193

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.31
  • Number of Estimates 3
  • High Estimate -0.29
  • Low Estimate -0.32
  • Prior Year -0.42
  • Growth Rate Est. (year over year) +26.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.13 +13.15%
on 05/12/22
3.27 -26.30%
on 04/26/22
-0.84 (-25.85%)
since 04/14/22
3-Month
2.13 +13.15%
on 05/12/22
4.72 -48.94%
on 03/30/22
-1.17 (-32.68%)
since 02/17/22
52-Week
2.10 +14.76%
on 12/15/21
6.94 -65.28%
on 05/18/21
-3.91 (-61.87%)
since 05/17/21

Most Recent Stories

More News
Gamida Cell Ltd. (GMDA) Q1 2022 Earnings Call Transcript

GMDA earnings call for the period ending March 31, 2022.

GMDA : 2.40 (+1.69%)
Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update...

GMDA : 2.40 (+1.69%)
Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, today will share preclinical...

GMDA : 2.40 (+1.69%)
Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live...

GMDA : 2.40 (+1.69%)
Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, today announced updated one-year...

GMDA : 2.40 (+1.69%)
Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that the U.S. Food...

GMDA : 2.40 (+1.69%)
Gamida Cell Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, today announced that updated...

GMDA : 2.40 (+1.69%)
Gamida Cell to Present Corporate Highlights and Participate in Panel Discussion at the Needham Healthcare Conference

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, announced that company management...

GMDA : 2.40 (+1.69%)
Pfizer (PFE) 2nd Ulcerative Colitis Study on Etrasimod Succeeds

Pfizer's (PFE) ELEVATE UC 52 is the second phase III study on etrasimod for ulcerative colitis to have met primary and key secondary endpoints.

PFE : 51.33 (+1.30%)
VRTX : 262.06 (+3.10%)
VYGR : 6.54 (+0.15%)
GMDA : 2.40 (+1.69%)
Has Champions Oncology, Inc. (CSBR) Outpaced Other Medical Stocks This Year?

Here is how Champions Oncology, Inc. (CSBR) and Gamida Cell (GMDA) have performed compared to their sector so far this year.

CSBR : 7.49 (+3.31%)
GMDA : 2.40 (+1.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Gamida Cell Ltd. is a biopharmaceutical company. It focuses on developing cell therapies to cure cancer and rare and serious hematologic diseases. The company's product pipeline consists of NiCord and NAM-NK which are in clinical stage. It operates primarily in the United States, the European Union and...

See More

Key Turning Points

3rd Resistance Point 2.55
2nd Resistance Point 2.50
1st Resistance Point 2.43
Last Price 2.40
1st Support Level 2.30
2nd Support Level 2.25
3rd Support Level 2.18

See More

52-Week High 6.94
Fibonacci 61.8% 5.09
Fibonacci 50% 4.52
Fibonacci 38.2% 3.95
Last Price 2.40
52-Week Low 2.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar